{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00307125",
      "OrgStudyIdInfo": {
        "OrgStudyId": "DAIT CTOT-02"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "CCTPT-02",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "NIAID"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "National Institute of Allergy and Infectious Diseases (NIAID)",
        "OrgClass": "NIH"
      },
      "BriefTitle": "Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies",
      "OfficialTitle": "B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2015",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2006"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2012",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2012",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "March 23, 2006",
      "StudyFirstSubmitQCDate": "March 23, 2006",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 27, 2006",
        "StudyFirstPostDateType": "Estimate"
      },
      "ResultsFirstSubmitDate": "February 27, 2015",
      "ResultsFirstSubmitQCDate": "March 11, 2015",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "March 23, 2015",
        "ResultsFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 11, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 23, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "National Institute of Allergy and Infectious Diseases (NIAID)",
        "LeadSponsorClass": "NIH"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Clinical Trials in Organ Transplantation",
            "CollaboratorClass": "NETWORK"
          },
          {
            "CollaboratorName": "Cooperative Clinical Trials in Pediatric Transplantation (CCTPT)",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of the transplanted kidney.The pilot study compares the use of rituximab (Rituxan®) + site-specific standard immunosuppression to placebo + site-specific standard immunosuppression in the treatment of circulating anti-HLA antibodies in subjects who develop de novo anti-HLA antibodies between 3-36 months after transplant.",
      "DetailedDescription": "Organ rejection occurs when a patient's body does not recognize the new organ and attacks it. Data suggest that the development of anti-human leukocyte antigen (HLA) antibodies is an early clinical indication that organ rejection may occur. Rituximab is a genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously; it is FDA-approved for the treatment of non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia (CLL); and Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.\n\nIn a previous small study, kidney transplant patients with either acute humoral rejection (AHR) or chronic humoral rejection (CHR) were given rituximab and other antilymphocyte therapy. Patients with AHR had lower or undetectable levels of circulating anti-HLA antibodies after study treatment, and patients with CHR had a sustained decrease of anti-HLA antibodies to undetectable after 6 to 9 months.\n\nThis study will evaluate the safety and efficacy of rituximab in 1.)preventing organ rejection and 2.)promoting long-term survival of donor kidneys in people who undergo kidney transplantation.\n\nThis study involves two stages:\n\nStage 1 begins 3 to 36 months after transplant. During Stage 1, blood collection will occur every 3 months for up to 36 months after transplant to test for anti-HLA antibodies. When these antibodies are detected twice within 1 month, the patient will undergo a baseline kidney biopsy and have his or her glomerular filtration rate (GFR) measured to determine kidney function. If a patient meets certain study criteria, he or she will enter Stage 2 (Pilot Treatment Study).\n\nIf anti-HLA antibodies are not detected in a patient's blood during Stage 1, the patient's participation will be complete.\n\nIn Stage 2, patients will receive site-specific standard immunosuppression plus randomization to either rituximab or placebo:\n\nAdult dosing (>18 years of age), will receive an intravenous infusion of 1000mg of rituximab on Days 0 and 14.\nPediatric dosing (<\\= than 18 years of age) will receive an intravenous infusion of 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses of rituximab on Days 0, 8, 15 and 22.\n\nAdult participants will have 7-9 study visits over 12-24 months. Pediatric participants will have 9-11 study visits over 12-24 months. A physical exam, medication history, adverse events assessment, and blood and urine collection will occur at all visits. A biopsy of the kidney transplant will occur at Stage 2 entry and Month 12.\n\nNote: Prior to January 2010, Stage 2 of this was a double-blind (double-masked) randomized pilot treatment study. As of January 2010 and beyond:\n\nsubjects were no longer being recruited in the placebo treatment arm\nall treatment assignments were unblinded and an open-label design commenced; therefore, medication assignments were open to the study participants as well as to the site clinical team.\nall study subjects who participated in the study prior to this change were informed of the change\nall subjects who were randomized to the placebo-controlled arm and continued to meet the pilot study eligibility criteria were provided the option to participate in the pilot treatment study."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Kidney Transplant",
          "Kidney Transplant Recipient",
          "Graft Function/Survival",
          "de Novo HLA Antibodies Development"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Organ Transplantation",
          "Graft function/survival",
          "Immunosuppression",
          "anti-CD20 (rituximab)"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "757",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Pilot Phase-Rituximab plus immunosuppression",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression is site-specific.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Rituximab plus immunosuppression"
              ]
            }
          },
          {
            "ArmGroupLabel": "Pilot Phase-Placebo plus immunosuppression",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Adult Placebo Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression is site-specific.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo plus immunosuppression"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Rituximab plus immunosuppression",
            "InterventionDescription": "Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma\n\nStandard immunosuppression is site-specific.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Pilot Phase-Rituximab plus immunosuppression"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Rituxan®",
                "MabThera®",
                "anti-CD20"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo plus immunosuppression",
            "InterventionDescription": "Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression is site-specific.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Pilot Phase-Placebo plus immunosuppression"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Placebo for rituximab"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "During Screening Phase: Incidence of Alloantibody Development",
            "PrimaryOutcomeDescription": "Data were analyzed for 653 participants from the screening phase of the study. This outcome looked at the number of kidney transplant recipients that developed de novo HLA antibodies (anti-HLA Ab) post-transplant. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen. Alloantibodies are important mediators of acute and chronic rejection.",
            "PrimaryOutcomeTimeFrame": "During screening window of 3-60 months post kidney transplant"
          },
          {
            "PrimaryOutcomeMeasure": "During Screening Phase: Timing of Alloantibody Development",
            "PrimaryOutcomeDescription": "Data were analyzed for 653 participants from the screening phase of the study. Of these, 79 (12%) developed de novo HLA-antibodies (anti-HLA Ab). This outcome looks at the average length of time (interval) from post kidney transplant until development of alloantibody. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen. Alloantibodies are important mediators of acute and chronic rejection",
            "PrimaryOutcomeTimeFrame": "During screening window of 3-60 months post kidney transplant"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With 50 Percent (%) Decrease in Circulating Anti-Human Leukocyte Antigen (HLA) Antibodies",
            "PrimaryOutcomeDescription": "Number of participants with 50% decrease in circulating anti-HLA antibodies at any time within the first 12 months post kidney transplant by LuminexTM Beads Method. Luminex assays for quantitation and detection of cytokine and signal transduction proteins. Presence of circulating antibodies is indicative of the transplant recipient's immune system responding to the transplanted organ as a foreign object or infection.",
            "PrimaryOutcomeTimeFrame": "1 year post treatment initiation"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of Deaths 12 Months Post Treatment Initiation",
            "SecondaryOutcomeDescription": "Number of participant deaths within 12 months post treatment initiation",
            "SecondaryOutcomeTimeFrame": "12 months post treatment initiation"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Participants Experiencing Graft Loss 12 Months Post Treatment Initiation",
            "SecondaryOutcomeDescription": "Number of participants with graft loss, defined as the need for dialysis for greater than 30 days duration, allograft nephrectomy, or the decision to withdraw immunosuppression due to graft failure within 12 month post treatment initiation",
            "SecondaryOutcomeTimeFrame": "1 year post treatment initiation"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Participants Experiencing Biopsy-proven Post-Transplant Lymphoproliferative Disease (PTLD)",
            "SecondaryOutcomeDescription": "Number of participants with PTLD within 12 month post treatment initiation. Diagnosis of PTLD was made by B cell proliferation after therapeutic immunosuppression.",
            "SecondaryOutcomeTimeFrame": "1 year post treatment initiation"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Participants Experiencing Loss of Peritubular Capillary (PTC) C4d Staining on Kidney Biopsy",
            "SecondaryOutcomeDescription": "Number of participants with loss of PTC C4d staining on kidney (renal) biopsy within 12 months post treatment initiation. PTC C4d staining on biopsy indicates organ rejection.",
            "SecondaryOutcomeTimeFrame": "1 year post treatment initiation"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Participants With Viral Replication of Cytomegalovirus (CMV)",
            "SecondaryOutcomeDescription": "Number of participants with viral replication of CMV within 12 month post treatment initiation. Measured by polymerase chain reaction (PCR) method. Evidence of viral replication is indicative of active CMV infection.",
            "SecondaryOutcomeTimeFrame": "1 year post treatment initiation"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Participants With Evidence of Viral Replication of Epstein-Barr Virus (EBV)",
            "SecondaryOutcomeDescription": "Number of participants with positive viral replication of EBV within 12 month post treatment initiation. Measured by polymerase chain reaction (PCR) method. Evidence of EBV viral replication is indicative of active infection.",
            "SecondaryOutcomeTimeFrame": "1 year post treatment initiation"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Participants With Viral Replication of Polyomavirus (BKV)",
            "SecondaryOutcomeDescription": "Number of participants with viral replication of BKV within 12 month post treatment initiation. Measured by polymerase chain reaction (PCR) method. Evidence of viral replication is indicative of a BKV infection. Polyomavirus BK is a significant pathogen in transplant recipients.",
            "SecondaryOutcomeTimeFrame": "1 year post treatment initiation"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Stage 1 Inclusion Criteria for All Participants:\n\nWilling to provide informed consent\nPreviously diagnosed end stage renal disease (ESRD)\nReceived kidney transplant within 3 and 36 months of study entry\nWilling to comply with the study protocol\nWilling to use acceptable forms of contraception during the study and for 12 months following rituximab/placebo therapy\nWilling to refrain from breastfeeding during the study and for 12 months following rituximab therapy\n\nStage 1 Inclusion Criteria for Pediatric Participants (<\\=18 Years of Age):\n\nParent or guardian willing to provide informed consent\nHave received all childhood vaccinations prior to study entry\n\nStage 2 Inclusion Criteria for Pilot Treatment Study:\n\nThree to 39 months post-transplant\nDeveloped new antibodies detected at two time points within 1 month between 3 to 36 months post-transplant\nNegative pregnancy test\n\nStage 1 Exclusion Criteria for All Participants:\n\nRecipient of a kidney from a donor older than 70 years of age\nMulti-organ transplant\nHistory of organ transplantation other than current kidney transplantation\nPrevious treatment with rituximab\nHistory of severe allergic reactions to monoclonal antibodies\nHistory of allergic reaction to iodine glomerular filtration rate (GFR) assay\nLack of intravenous (IV) access\nSensitized to greater than 5% Panel Reactive Antibody (PRA) within 12 weeks prior to transplant\nHistory of recurrent bacterial or other significant infections\nKnown active bacterial, viral, fungal, mycobacterial, or other infection (including tuberculosis [TB] or atypical mycobacterial disease) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of study entry. Patients with fungal infections of nail beds are not excluded.\nHIV infected\nSurface antigen positive for hepatitis B virus (HBV)\nAntibody positive for hepatitis C virus (HCV)\nHistory of drug, alcohol, or chemical abuse within 6 months prior to study entry\nHistory of cancer. Patients with adequately treated in situ cervical carcinoma or adequately treated basal or squamous cell carcinoma of the skin are not excluded.\nClinically significant cardiovascular or pulmonary disease\nEvidence of urinary tract obstruction causing decreased kidney function, unless corrected by study entry\nAny other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would contraindicate use of an investigational drug, may affect interpretation of study results, or put the patient at high risk for treatment complications\nHistory of psychiatric disorder that may interfere with participation in the study\nHistory of nonadherence to prescribed regimens\nUse of other investigational drugs within 4 weeks of study entry\nReceived any licensed or investigational live attenuated vaccine within 2 months of study entry.\n\nStage 2 Exclusion Criteria for All Participants:\n\nPrevious treatment with rituximab\nImmunoglobulin Levels <500mg/dL (Combined IgM, IgG, IgA, IgE, IgD)\nHistory of severe allergic reactions to monoclonal antibodies\nHistory of cancer. Patients with adequately treated in situ cervical carcinoma or adequately treated basal or squamous cell carcinoma of the skin are not excluded.\nActive systemic infection at the time of entry into Stage 2\nRecurrent or de novo glomerular disease or Banff Grade III chronic rejection other than chronic humoral rejection (CHR) indicated in baseline kidney biopsy post-transplant\nHistory of post-transplant lymphoproliferative disease (PTLD)\nSerum creatinine of 3.0 mg/dl or greater OR GFR less than 25 ml/min at the time of entry into Stage 2\nHemoglobin less than 8.5 g/dl\nPlatelets less than 80,000 cells/mm^3\nWhite blood cell count less than 3,000 cells/mm^3\nAST or ALT 2.5 times the upper limit of normal at study entry\nPregnant or breast-feeding\nAbsolute neutrophil count less than 1000/mm^3\n\nStage 2 Exclusion Criteria for Pediatric Participants (<\\=18 Years of Age):\n\nPositive test for parvovirus (B19) by PCR in the blood.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "5 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Mohamed H. Sayegh, MD",
            "OverallOfficialAffiliation": "Brigham and Women's Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "William Harmon, MD",
            "OverallOfficialAffiliation": "Boston Children's Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Anil Chandraker, MD",
            "OverallOfficialAffiliation": "Brigham and Women's Hospital",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Alabama, Pediatric Nephrology",
            "LocationCity": "Birmingham",
            "LocationState": "Alabama",
            "LocationZip": "35294",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Alabama",
            "LocationCity": "Birmingham",
            "LocationState": "Alabama",
            "LocationZip": "35294",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of California, San Francisco",
            "LocationCity": "San Francisco",
            "LocationState": "California",
            "LocationZip": "94143",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Florida",
            "LocationCity": "Gainesville",
            "LocationState": "Florida",
            "LocationZip": "32601",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Illinois",
            "LocationCity": "Chicago",
            "LocationState": "Illinois",
            "LocationZip": "60607",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Northwestern University",
            "LocationCity": "Chicago",
            "LocationState": "Illinois",
            "LocationZip": "60611",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Maryland",
            "LocationCity": "Baltimore",
            "LocationState": "Maryland",
            "LocationZip": "21201",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Massachusetts General Hospital",
            "LocationCity": "Boston",
            "LocationState": "Massachusetts",
            "LocationZip": "02114",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Brigham and Women's Hospital",
            "LocationCity": "Boston",
            "LocationState": "Massachusetts",
            "LocationZip": "02115",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Children's Hospital Boston",
            "LocationCity": "Boston",
            "LocationState": "Massachusetts",
            "LocationZip": "02115",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Beth Israel Deaconess Medical Center",
            "LocationCity": "Boston",
            "LocationState": "Massachusetts",
            "LocationZip": "02215",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Saint Barnabas Medical Center",
            "LocationCity": "Livingston",
            "LocationState": "New Jersey",
            "LocationZip": "07039",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Legacy Transplant Services",
            "LocationCity": "Portland",
            "LocationState": "Oregon",
            "LocationZip": "97210",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Oregon Health Science University",
            "LocationCity": "Portland",
            "LocationState": "Oregon",
            "LocationZip": "97219",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Children's Hospital of Philadelphia",
            "LocationCity": "Philadelphia",
            "LocationState": "Pennsylvania",
            "LocationZip": "19104",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "The Methodist Hospital",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77030",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Children's Hospital and Regional Medical Center",
            "LocationCity": "Seattle",
            "LocationState": "Washington",
            "LocationZip": "98105",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "12438971",
            "ReferenceType": "background",
            "ReferenceCitation": "Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation. 2002 Oct 27;74(8):1192-4."
          },
          {
            "ReferencePMID": "12394606",
            "ReferenceType": "background",
            "ReferenceCitation": "Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002 Nov;11(6):609-18. Review."
          },
          {
            "ReferencePMID": "12698094",
            "ReferenceType": "background",
            "ReferenceCitation": "Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation. 2003 Apr 15;75(7):1034-40."
          },
          {
            "ReferencePMID": "28346714",
            "ReferenceType": "derived",
            "ReferenceCitation": "Fishman JA, Iklé DN, Wilkinson RA. Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study. Transpl Int. 2017 Jul;30(7):689-694. doi: 10.1111/tri.12959. Epub 2017 May 2."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Click here for the Clinical Trials in Organ Transplantation (CTOT) public Web site",
            "SeeAlsoLinkURL": "http://www.ctotstudies.org"
          }
        ]
      }
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowPreAssignmentDetails": "From the screening cohort, N=22 subjects were enrolled in the treatment phase of the study (Stage 2: Pilot Study). Refer to Detailed Description and Eligibility Sections for more details.",
      "FlowRecruitmentDetails": "N=757 subjects were enrolled in the screening phase (Stage 1: Screening) of the study and followed for development of de novo anti-HLA antibodies for up to 60 months post-kidney (renal) transplant.N=22 subjects from the screening cohort were enrolled in the treatment phase. Refer to Detailed Description and Eligibility Sections for more details.",
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Screening Phase",
            "FlowGroupDescription": "Kidney (renal) transplant recipients with no detectable anti-human leukocyte antigen (HLA) antibodies prior to transplant. Participants were screened for the development of anti-HLA antibodies once every 3 months up to 36 months post-transplantation and yearly thereafter until Month 60."
          },
          {
            "FlowGroupId": "FG001",
            "FlowGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
            "FlowGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
          },
          {
            "FlowGroupId": "FG002",
            "FlowGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
            "FlowGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Screening Phase",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "757"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "303"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "454"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "0"
                      }
                    ]
                  }
                }
              ]
            },
            "FlowDropWithdrawList": {
              "FlowDropWithdraw": [
                {
                  "FlowDropWithdrawType": "Adverse Event",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Protocol Violation",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "27"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Lost to Follow-up",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "87"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Death",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "10"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Withdrawal by Subject",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "77"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Physician Decision",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "26"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Sponsor Decision",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "4"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Study Terminated",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "17"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Graft Loss",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "3"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Graft Failure",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "8"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Follow-up period ended on Dec 31, 2011",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "83"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Scheduling issues/Non-compliance",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "55"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Moved or transferred facilities",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "34"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Received Pancreas Transplant",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "8"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Ineligible for pilot",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "4"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Try to get pregnant",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Developed acute leukemia",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Metastatic colon cancer",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Malignancy",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "PAK",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Ineligible",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Screen Error",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Sample of Anti-HLA Ab was not obtained",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "AMR and treated with rituximab",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Coronary artery bypass",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "FlowPeriodTitle": "Pilot Phase",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "15"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "7"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementComment": "2 participants had reduced follow-up",
                        "FlowAchievementNumSubjects": "13"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementComment": "1 participant had reduced follow-up",
                        "FlowAchievementNumSubjects": "6"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "2"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "1"
                      }
                    ]
                  }
                }
              ]
            },
            "FlowDropWithdrawList": {
              "FlowDropWithdraw": [
                {
                  "FlowDropWithdrawType": "Lost to Follow-up",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Withdrawal by Subject",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG002",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselinePopulationDescription": "Intent-to-treat",
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
            "BaselineGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
          },
          {
            "BaselineGroupId": "BG001",
            "BaselineGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
            "BaselineGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
          },
          {
            "BaselineGroupId": "BG002",
            "BaselineGroupTitle": "Total",
            "BaselineGroupDescription": "Total of all reporting groups"
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "15"
                },
                {
                  "BaselineDenomCountGroupId": "BG001",
                  "BaselineDenomCountValue": "7"
                },
                {
                  "BaselineDenomCountGroupId": "BG002",
                  "BaselineDenomCountValue": "22"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Categorical",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "<=18 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "4"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Between 18 and 65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "10"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "6"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "16"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": ">=65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Age, Continuous",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "years",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "41.4",
                              "BaselineMeasurementSpread": "19.5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "49.0",
                              "BaselineMeasurementSpread": "15.0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "43.8",
                              "BaselineMeasurementSpread": "18.2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "5"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "12"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "17"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Region of Enrollment",
            "BaselineMeasureParamType": "Number",
            "BaselineMeasureUnitOfMeasure": "participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassTitle": "United States",
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "15"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "7"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "22"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "During Screening Phase: Incidence of Alloantibody Development",
            "OutcomeMeasureDescription": "Data were analyzed for 653 participants from the screening phase of the study. This outcome looked at the number of kidney transplant recipients that developed de novo HLA antibodies (anti-HLA Ab) post-transplant. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen. Alloantibodies are important mediators of acute and chronic rejection.",
            "OutcomeMeasurePopulationDescription": "Screening sample",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "During screening window of 3-60 months post kidney transplant",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Screening Phase",
                  "OutcomeGroupDescription": "Participants who were analyzed during the screening phase/stage of the study"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "653"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "79"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "During Screening Phase: Timing of Alloantibody Development",
            "OutcomeMeasureDescription": "Data were analyzed for 653 participants from the screening phase of the study. Of these, 79 (12%) developed de novo HLA-antibodies (anti-HLA Ab). This outcome looks at the average length of time (interval) from post kidney transplant until development of alloantibody. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen. Alloantibodies are important mediators of acute and chronic rejection",
            "OutcomeMeasurePopulationDescription": "Screening sample",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "Standard Deviation",
            "OutcomeMeasureUnitOfMeasure": "Months",
            "OutcomeMeasureTimeFrame": "During screening window of 3-60 months post kidney transplant",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Screening Phase",
                  "OutcomeGroupDescription": "Participants who were analyzed during the screening phase of the study"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "653"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "16.2",
                              "OutcomeMeasurementSpread": "9.9"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Number of Participants With 50 Percent (%) Decrease in Circulating Anti-Human Leukocyte Antigen (HLA) Antibodies",
            "OutcomeMeasureDescription": "Number of participants with 50% decrease in circulating anti-HLA antibodies at any time within the first 12 months post kidney transplant by LuminexTM Beads Method. Luminex assays for quantitation and detection of cytokine and signal transduction proteins. Presence of circulating antibodies is indicative of the transplant recipient's immune system responding to the transplanted organ as a foreign object or infection.",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeAnalysisList": {
              "OutcomeAnalysis": [
                {
                  "OutcomeAnalysisGroupIdList": {
                    "OutcomeAnalysisGroupId": [
                      "OG000",
                      "OG001"
                    ]
                  },
                  "OutcomeAnalysisGroupDescription": "Analysis by Fisher's exact test counting participants with 50% decrease in anti-HLA antibodies at any time within 12 months post treatment initiation",
                  "OutcomeAnalysisTestedNonInferiority": "No",
                  "OutcomeAnalysisNonInferiorityType": "Superiority or Other",
                  "OutcomeAnalysisPValue": ">0.999",
                  "OutcomeAnalysisStatisticalMethod": "Fisher Exact",
                  "OutcomeAnalysisCINumSides": "2-Sided"
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Deaths 12 Months Post Treatment Initiation",
            "OutcomeMeasureDescription": "Number of participant deaths within 12 months post treatment initiation",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "12 months post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Participants Experiencing Graft Loss 12 Months Post Treatment Initiation",
            "OutcomeMeasureDescription": "Number of participants with graft loss, defined as the need for dialysis for greater than 30 days duration, allograft nephrectomy, or the decision to withdraw immunosuppression due to graft failure within 12 month post treatment initiation",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects ≤18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject ≤18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression is site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Participants Experiencing Biopsy-proven Post-Transplant Lymphoproliferative Disease (PTLD)",
            "OutcomeMeasureDescription": "Number of participants with PTLD within 12 month post treatment initiation. Diagnosis of PTLD was made by B cell proliferation after therapeutic immunosuppression.",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Participants Experiencing Loss of Peritubular Capillary (PTC) C4d Staining on Kidney Biopsy",
            "OutcomeMeasureDescription": "Number of participants with loss of PTC C4d staining on kidney (renal) biopsy within 12 months post treatment initiation. PTC C4d staining on biopsy indicates organ rejection.",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Participants With Viral Replication of Cytomegalovirus (CMV)",
            "OutcomeMeasureDescription": "Number of participants with viral replication of CMV within 12 month post treatment initiation. Measured by polymerase chain reaction (PCR) method. Evidence of viral replication is indicative of active CMV infection.",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Positive",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Negative",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "12"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "5"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeAnalysisList": {
              "OutcomeAnalysis": [
                {
                  "OutcomeAnalysisGroupIdList": {
                    "OutcomeAnalysisGroupId": [
                      "OG000",
                      "OG001"
                    ]
                  },
                  "OutcomeAnalysisTestedNonInferiority": "No",
                  "OutcomeAnalysisNonInferiorityType": "Superiority or Other",
                  "OutcomeAnalysisPValue": ">0.999",
                  "OutcomeAnalysisStatisticalMethod": "Fisher Exact",
                  "OutcomeAnalysisCINumSides": "2-Sided"
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Participants With Evidence of Viral Replication of Epstein-Barr Virus (EBV)",
            "OutcomeMeasureDescription": "Number of participants with positive viral replication of EBV within 12 month post treatment initiation. Measured by polymerase chain reaction (PCR) method. Evidence of EBV viral replication is indicative of active infection.",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Positive",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "7"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Negative",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeAnalysisList": {
              "OutcomeAnalysis": [
                {
                  "OutcomeAnalysisGroupIdList": {
                    "OutcomeAnalysisGroupId": [
                      "OG000",
                      "OG001"
                    ]
                  },
                  "OutcomeAnalysisTestedNonInferiority": "No",
                  "OutcomeAnalysisNonInferiorityType": "Superiority or Other",
                  "OutcomeAnalysisPValue": ">0.999",
                  "OutcomeAnalysisStatisticalMethod": "Fisher Exact",
                  "OutcomeAnalysisCINumSides": "2-Sided"
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Number of Participants With Viral Replication of Polyomavirus (BKV)",
            "OutcomeMeasureDescription": "Number of participants with viral replication of BKV within 12 month post treatment initiation. Measured by polymerase chain reaction (PCR) method. Evidence of viral replication is indicative of a BKV infection. Polyomavirus BK is a significant pathogen in transplant recipients.",
            "OutcomeMeasurePopulationDescription": "Intent-to-treat",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "1 year post treatment initiation",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
                  "OutcomeGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "15"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "7"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Positive",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Negative",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "15"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "7"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "5",
      "EventsTimeFrame": "From kidney (renal) transplant to the end of study",
      "EventsDescription": "Adverse events methods:\n\nObserving the participant\nQuestioning the participant, which should be done in an objective manner.\nReceiving an unsolicited complaint from the participant.\nAn abnormal value or result from a clinical or laboratory evaluation.",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Pilot Phase-Rituximab Plus Immunosuppression",
            "EventGroupDescription": "Adult Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subjects <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific.",
            "EventGroupSeriousNumAffected": "5",
            "EventGroupSeriousNumAtRisk": "15",
            "EventGroupOtherNumAffected": "3",
            "EventGroupOtherNumAtRisk": "15"
          },
          {
            "EventGroupId": "EG001",
            "EventGroupTitle": "Pilot Phase-Placebo Plus Immunosuppression",
            "EventGroupDescription": "Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).\n\nStandard immunosuppression was site-specific.",
            "EventGroupSeriousNumAffected": "1",
            "EventGroupSeriousNumAtRisk": "7",
            "EventGroupOtherNumAffected": "2",
            "EventGroupOtherNumAtRisk": "7"
          }
        ]
      },
      "SeriousEventList": {
        "SeriousEvent": [
          {
            "SeriousEventTerm": "Duodenal fistula",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Infusion related reaction",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Transplant rejection",
            "SeriousEventOrganSystem": "Immune system disorders",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Chlamydial pelvic inflammatory disease",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pneumonia",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Sepsis",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Prostate cancer",
            "SeriousEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "SeriousEventSourceVocabulary": "MedDRA 11.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "15"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "7"
                }
              ]
            }
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Diarrhoea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 11.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "15"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "7"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pharyngolaryngeal pain",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "MedDRA 11.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "15"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "7"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "No",
        "AgreementRestrictiveAgreement": "No"
      },
      "PointOfContact": {
        "PointOfContactTitle": "Director, Clinical Research Operations Program (CROP)",
        "PointOfContactOrganization": "DAIT/NIAID",
        "PointOfContactEMail": "DAITClinicalTrialsGov@niaid.nih.gov",
        "PointOfContactPhone": "301-594-7669"
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000069283",
            "InterventionMeshTerm": "Rituximab"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000074322",
            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M373",
            "InterventionBrowseLeafName": "Rituximab",
            "InterventionBrowseLeafAsFound": "Test",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3377",
            "InterventionBrowseLeafName": "Antibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9336",
            "InterventionBrowseLeafName": "Immunoglobulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3382",
            "InterventionBrowseLeafName": "Antibodies, Monoclonal",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9702",
            "InterventionBrowseLeafName": "Isoantibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1346",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}